Leiden, The Netherlands, Dec. 10, 2013 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that an Extraordinary General Meeting of Shareholders will be held on January 23rd, 2014 at 14:00 hrs. CET at the offices of Prosensa Holding N.V.,… Continue reading Prosensa Announces Extraordinary Shareholders Meeting to Appoint Dr. Georges Gemayel
Blog posts
Prosensa and Partners Awarded Second European Consortium FP7 Research Grant
BIOIMAGE-NMD project receives EUR 6M to develop biomarkers to monitor effectiveness of DMD treatments Leiden, The Netherlands and Newcastle, UK, Nov. 25, 2013 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, and Newcastle University, UK, have announced the award of a… Continue reading Prosensa and Partners Awarded Second European Consortium FP7 Research Grant
Prosensa Announces Third Quarter 2013 Financial Results and Recent Corporate Developments – Working Closely With Collaboration Partner GSK to Analyze Benefit-to-Risk Profile of drisapersen Across All Studies –
LEIDEN, The Netherlands, Nov. 18, 2013 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (Nasdaq:RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported financial results for the quarter ending September 30, 2013. “Together with our collaboration partner, GSK, the benefit-to-risk profile of drisapersen treatment across all studies is… Continue reading Prosensa Announces Third Quarter 2013 Financial Results and Recent Corporate Developments – Working Closely With Collaboration Partner GSK to Analyze Benefit-to-Risk Profile of drisapersen Across All Studies –
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR™ – 6 month follow-up data expected in H1 2014 –
Amsterdam, The Netherlands, November 18, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma’s lead program, ATIR™, is a cell-based product designed to enable stem… Continue reading Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR™ – 6 month follow-up data expected in H1 2014 –
Prosensa Awarded Best Biotech Pipeline 2013 at the Rare & Orphan Advocacy and Research (ROAR) Awards
Leiden, The Netherlands, Nov. 15, 2013 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, has been awarded Best Biotech Pipeline 2013 in the Rare & Orphan Advocacy and Research (ROAR) Awards.
